DHA and EPA Formulations for Acute Cardiovascular and Cognitive Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for improving cardiovascular and cognitive function primarily focus on chronic supplementation with long-chain polyunsaturated fatty acids (LCPUFAs), neglecting the potential for acute beneficial effects.

Innovation Solution

Administering LCPUFAs, particularly omega-3 fatty acids like DHA and EPA, in forms such as triglycerides, phospholipids, or ethyl esters, either naturally sourced or synthetic, in doses of at least 500 mg, often microencapsulated, to achieve rapid improvements in cardiovascular and cognitive functions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chronic supplementation with LCPUFAs is used, then cardiovascular and cognitive health benefits are improved, but the time required to achieve effects is extended over weeks to years

Engineering Contradiction:

Improvehealth benefitsVSAvoidtime to achieve effects

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by pre-formulating LCPUFAs in highly bioavailable forms (ethyl esters, phospholipids, triglycerides) that are optimized for rapid absorption and tissue incorporation. This preliminary preparation of the fatty acids in optimal molecular forms enables acute effects within hours rather than requiring chronic supplementation over weeks to years, while maintaining the same cardiovascular and cognitive health benefits

Inventive Principle:

Principle #10Preliminary action

2Speed

If high doses of LCPUFAs are administered to achieve acute effects, then the speed of action is improved, but the quantity of substance required increases

Engineering Contradiction:

Improvespeed of actionVSAvoiddose required

Core Design Contradiction:

SpeedVSQuantity of substance

Solution Approach 1:

The patent applies parameter changes by modifying the molecular form and physical state of LCPUFAs (converting to ethyl esters, phospholipids, and triglyceride forms with specific chain lengths and degrees of unsaturation). These parameter changes in the fatty acid structure dramatically improve bioavailability and tissue incorporation rates, enabling acute effects at lower doses rather than requiring high quantities of conventional fish oil supplements

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12564566B2Uses of long-chain polyunsaturated fatty acids

Publication Date: 2026.03.03 SWINBURNE UNIVERSITY OF TECHNOLOGY

AI summary

The present invention is directed to methods of acutely improving or enhancing cardiovascular and/or cognitive function, comprising the administration of LCPUFAs, in particular docosahexanoic acid (DHA), uses and compositions thereof.